Clinical Research Directory
Browse clinical research sites, groups, and studies.
DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies
Sponsor: Cambridge University Hospitals NHS Foundation Trust
Summary
What is the research question? Semaglutide and tirzepatide cause weight loss and blood pressure reduction. However, weight loss only partially explains the blood pressure reduction. Based on previous studies, there might be direct effects in the cardiovascular system. In forearm blood flow studies, semaglutide and tirzepatide will be infused into the brachial artery to investigate their effects on the function of blood vessels. In systemic studies, semaglutide and tirzepatide will be infused into systemic circulation to investigate their effects on heart and blood vessels. There are three different populations being looked at for this study: participants with normal weight and normal blood pressure, participants with obesity and normal blood pressure, and participants with obesity and high blood pressure. There are six sub-studies each with different visit schedules. The minimum participant study duration (including follow-up phone call) would be 2 days, while the maximum participant study duration would be approximately 2 - 2.5 months. The overall study duration is expected to be approximately 18 months.
Key Details
Gender
All
Age Range
18 Years - 50 Years
Study Type
INTERVENTIONAL
Enrollment
112
Start Date
2026-03
Completion Date
2028-04
Last Updated
2026-03-19
Healthy Volunteers
Yes
Conditions
Interventions
semaglutide
Semaglutide: GLP-1 analogue
Tirzepatide
Tirzepatide: dual GIP/GLP-1 receptor agonist
Locations (1)
Addenbrooke's Hospital
Cambridge, Cambridgeshire, United Kingdom